Ignite Creation Date:
2024-05-06 @ 6:29 PM
Last Modification Date:
2024-10-26 @ 2:49 PM
Study NCT ID:
NCT05685420
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-01-17
First Post:
2023-01-06
Brief Title:
Extension Study of Herombopag for Pediatric Patients With Chronic Immune Thrombocytopenia
Sponsor:
Jiangsu HengRui Medicine Co Ltd
Organization:
Jiangsu HengRui Medicine Co Ltd
Study Overview
Official Title:
Extension Study of Herombopag in Children and Adolescents With Chronic Primary Immune Thrombocytopenia
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main purpose of this extended study is to enable subjects who are currently receiving the PartB experimental drug in the HR-TPO-ITP-III-PED clinical trial To continue receiving the experimental drug after the completion of the clinical trial if they benefit from the treatment at the end of the clinical trialUntil the study physician determines that the subject has failed treatment or that the subject can no longer benefit from treatment or extends the study treatment for 6 monthsIn addition the secondary purpose of this extended study was to observe the long-term efficacy and safety of tripodal in children and adolescents
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None